DESTINY-Breast03 Phase 3 Study Results
Background
·
•
HER3 is overexpressed in many types of cancer, including 30% to 50% of breast cancers
Overexpression of HER3 in breast cancer is associated with poor prognosis 4,5
•
No HER3-directed therapies have been approved for the treatment of any cancer
Daiichi-Sankyo
•
.
U31402-A-J101 (NCT02980341/JapicCTI-163401) is an ongoing phase 1/2 study of
HER3-DXd in patients with HER3-expressing metastatic breast cancer
Early data from the dose escalation, dose finding, 6 and dose expansion parts showed promising antitumor activity
and a manageable safety profile in heavily pretreated patients
•
Here we report mature data across all study cohorts, providing consolidated data among
patients with a range of breast cancer subtypes
•
As of the August 16, 2021, data cutoff, the median follow-up for all patients was 31.9 months (range, 15-56 months)
BC, breast cancer.
1. Naidu R, et al. Br J Cancer. 1998;78(10):1385-1390. 2. Travis A, et al. Br J Cancer. 1996;74(2):229-233. 3. Kogawa T, et al. ASCO 2018. Poster 2512. 4. Witton CJ, et al. J Pathol. 2003;200(3): 290-297.
5. Ocana A, et al. J Natl Cancer Inst. 2013;105(4):266-273. 6. Masuda N, et al. SABCS 2018. Poster PD1-03. 7. Krop IE, et al. SABCS 2020. Poster PD1-09.
ASCO 2022 #1002 Oral
84
==View entire presentation